XTND

1.6507.82%
PM

Peter Morgan Kash

Independent Chairman of the Board

Dr. Peter Morgan Kash, Ed.D, MBA, is Vice Chairman of iOncologi, Inc. Dr. Kash serves as Independent Chairman of the Board at Xtend AI Robotics, Inc. from December 2024. Dr. Kash serves as Independent Director of Healthcare Capital Corp. Dr. Kash has been an Independent Director of Healthcare Capital Corp Delaware since January 15, 2021. He served as Managing Director of Castle Hill Capital Partners, Inc until 2018. Dr. Kash served as the President of Riverbank Capital Securities, Inc. until 2011. He was Non-Executive Director at Firebrick Pharma Limited since February 17, 2020 until October 18, 2021. Dr. Kash is an Advisor of BeaconVentureCapital.com. He is an Adjunct Professor of Entrepreneurship at the Sy Syms School of Business. From 1989 to 1991, he served as an Associate Professor of Marketing at the Polytechnic University. Dr. Kash has worked on Wall Street for many years including at Shearson Lehman Hutton and Paramount Capital. He served as Senior Managing Director and Director of Paramount Capital Asset Management, Inc. Dr. Morgan was a Partner at Two River Group Holdings, LLC. He co-founded Two River Group Holdings in September 2004 and previously served as its chairman. In addition, he served as an Adjunct Professor of Entrepreneurship and International Venture Capital at the Wharton School of the University of Pennsylvania from 1996 to 2000 and was a Visiting Professor of Entrepreneurship at the Graduate School of Business at Nihon University in Tokyo, Japan from 1999 to 2001. Dr. Kash was Entrepreneur in Residence at Pace University Spring 2001 and at Ball State University in May 2002. He was the Senior Managing Director of Paramount Capital Investments, L.L.C. and Paramount Capital Inc. Prior to Co-Founding Two River, from June 1992 to September 2004. Dr. Kash was the Senior Managing Director at Paramount BioCapital Investments, LLC, as well as Paramount BioCapital, Inc. At Paramount he co-founded and financed PolaRx Biopharmaceuticals, developing the first cancer drug from China, Trisenox, approved by the FDA. He serves as the Chairman and Director of Intrac Inc. He served as Chairman of the Board of Directors at Danube Pharmaceuticals, Inc. until June 2008. He served as Vice Chairman and Director of IDDS since December 2003 and February 2001 respectively. He served as a Vice Chairman of Javelin Pharmaceuticals, Inc. He served as a Director of Keryx Biopharmaceuticals Inc. since October 1998 and was its Vice Chairman until September 2004. He has also co-founded Keryx Biopharmaceuticals and has served on the boards of ID Vaccines. He served as Vice Chairman of Velcera, Inc. until July 9, 2007. He serves as a Director of Cortiva Group, Inc., Kirax Corporation, Pear Tree Pharmaceuticals, Inc. and Danube Pharmaceuticals, Inc. Dr. Kash has been a Director of Innovative Drug Delivery Systems, Inc. since February 2001. He served as Member of Advisory Board of DarioHealth Corp. He serves as Member of Advisory Board of TriGlobal Strategic Ventures. Dr. Kash also serves on the Board of Keren-Or. He serves as Executive Chairman of timeflash LLC (formerly, Time Flash LLC) and served as its Executive Director. He serves as a Member of Advisory Board at DarioHealth Corp. and served as its Director from November 24, 2014 to February 25, 2015. Dr. Kash has also served on the Board of Directors of several privately held and publicly traded biotechnology companies including Kirax Corporation. He served as the Chairman of Nile Therapeutics, Inc and served as its Director since August 2005. He served as Director of DarioHealth Corp. since November 24, 2014 until February 2015. He served as Director of Capricor Therapeutics, Inc. since November 20, 2013 and Arno Therapeutics, Inc. until April 25, 2011. He served as a Director of Intercept Pharmaceuticals, Inc. and Valcom, Inc. He served as a Director of Javelin Pharmaceuticals, Inc. from December 2004 to December 11, 2006. Dr. Kash has also served as a Director of several offshore investment vehicles. In 2001, he published his book, Make Your Own Luck (Prentice Hall), which has since been translated into five languages. He is the Vice-Chairman of TargImmune Therapeutics (Switzerland), which he co-founded in January 2016. Since September 2017, he has also served as Managing Director of FFD, LLC in addition to serving as a member of the advisory board of Gravitas Global Advisors LLC since August 2018. He was the formerly a co-founder and partner of Two River Group and President of Capital Securities specializing in creating and financing several biotech companies including: Kite Pharma, Edgemont Pharmaceuticals and Intercept Pharmaceuticals. Dr. Kash has authored several books and has served many years as an Adjunct/Visiting Professor of Entrepreneurship at such leading institutions as: the Wharton School of Business and Hebrew University (Israel). Dr. Kash earned a B.S. in Management Science at the State University of New York at Binghamton from 1981 to 1983 and an M.B.A. in International Banking and Finance at Lubin School of Business at Pace University from 1987 to 1989 and his PhD from the Azrieli School of Education at Yeshiva University.

Positions